ClassID:

20147

A61K9/5005 - CPC Classification

Classification description:

Medicinal preparations characterised by special physical form; Preparations in capsules, e.g. of gelatin, of chocolate; Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals Wall or coating material

Sub-classes:
Recent Application in this class:
#1
20260151407
2026-06-04

TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION

#2
20260034085
2026-02-05

LEVODOPA DOSING REGIMEN

#3
20250387453
2025-12-25

Methods and Compositions for Treating Diabetes

#4
20250152543
2025-05-15

LEVODOPA DOSING REGIMEN

#5
20250152542
2025-05-15

LEVODOPA DOSING REGIMEN

#6
20250152541
2025-05-15

Levodopa dosing regimen

#7
20250152540
2025-05-15

LEVODOPA DOSING REGIMEN

#8
20250152539
2025-05-15

LEVODOPA DOSING REGIMEN

#9
20250000831
2025-01-02

Levodopa dosing regimen

#10
20240423940
2024-12-26

Levodopa dosing regimen

#11
20240423939
2024-12-26

Levodopa dosing regimen

#12
20240398744
2024-12-05

Levodopa dosing regimen

#13
20240398743
2024-12-05

Levodopa dosing regimen

#14
20240315999
2024-09-26

LEVODOPA DOSAGE FORM

#15
20240299503
2024-09-12

Methods and Compositions for Treating Diabetes

#16
20240277648
2024-08-22

Levodopa dosing regimen

#17
20240033310
2024-02-01

HETEROGENEOUS MICROPARTICLES, AND SYSTEMS AND METHODS OF MAKING AND USE THEREOF

#18
20230346715
2023-11-02

TRANSDERMAL FORMULATION FOR THE TREATMENT OF PAIN AND/OR INFLAMMATION

#19
20230256032
2023-08-17

PREVOTELLA HISTICOLA STRAIN C AS AN ORAL THERAPY FOR INFLAMMATORY DISEASES

#20
20230210956
2023-07-06

METHODS AND COMPOSITIONS FOR TREATING DIABETES

#21
20230210775
2023-07-06

EXTRUDED DEPOT FORM FOR CONTROLLED ACTIVE SUBSTANCE RELEASE

#22
20230054825
2023-02-23

Levodopa dosing regimen

#23
20230051314
2023-02-16

BIODEGRADABLE MICROCAPSULES

#24
20220175959
2022-06-09

Microparticles and nanoparticles having sulfate groups on the surface

#25
20210401770
2021-12-30

Transdermal formulation for the treatment of pain and/or inflammation

#26
20210077588
2021-03-18

Methods and compositions for treating diabetes

#27
20210046015
2021-02-18

Drug delivery systems comprising solid solutions of weakly basic drugs

#28
20200405660
2020-12-31

Transdermal formulation for the treatment of pain and/or inflammation

#29
20200376046
2020-12-03

PROBIOTIC RECOLONISATION THERAPY

#30
20200338033
2020-10-29

Enterically coated cysteamine, cystamine and derivatives thereof

#31
20190388559
2019-12-26

ENCAPSULATION OF METAL OXIDE NANOMATERIALS FOR CONTROLLED RELEASE AND TARGETED DELIVERY

#32
20190374615
2019-12-12

Methods and Compositions for Treating Diabetes

#33
20190290704
2019-09-26

Probiotic recolonisation therapy

#34
20190159979
2019-05-30

Reloadable microcapsules

#35
20190151238
2019-05-23

Treatment of inflammatory bowel disease

#36
20190117828
2019-04-25

Glass Composites for Tissue Augmentation, Biomedical and Cosmetic Applications

#37
20190060264
2019-02-28

Enterically coated cysteamine, cystamine and derivatives thereof

#38
20180344782
2018-12-06

Probiotic recolonisation therapy

#39
20180344593
2018-12-06

Products containing charged polymer complex microcapsules and method of use

#40
20180161746
2018-06-14

Microcapsules modified with nanomaterial for controlled release of active agent and process for preparation thereof

#41
20180125784
2018-05-10

Delayed release pharmaceutical formulation and methods of making and using same

#42
20170354755
2017-12-14

Glass composites for tissue augmentation, biomedical and cosmetic applications

#43
20170354610
2017-12-14

Microcellular microstructure and method for manufacturing same

#44
20170348204
2017-12-07

Microcapsules comprising a water-immiscible core and a wall comprising the salt of a lewis acid and a lewis base

#45
20170319524
2017-11-09

Enterically coated cysteamine, cystamine and derivatives thereof

#46
20170319523
2017-11-09

Enterically coated cysteamine, cystamine and derivatives thereof

#47
20170319522
2017-11-09

Enterically coated cysteamine, cystamine and derivatives thereof

#48
20170095467
2017-04-06

ENCAPSULATION OF ISOQUINOLINE ALKALOIDS

#49
20170042845
2017-02-16

Enterically coated cysteamine, cystamine and derivatives thereof

#50
20170007631
2017-01-12

Oral formulations Mimetic of Roux-en-Y gastric bypass actions on the ileal brake; Compositions, Methods of Treatment, Diagnostics and Systems for treatment of metabolic syndrome manifestations including insulin resistance, fatty liver disease, hyperlipidemia, and T2D

#51
20160375068
2016-12-29

Probiotic recolonisation therapy

#52
20160375067
2016-12-29

Probiotic recolonisation therapy

#53
20160375066
2016-12-29

Probiotic recolonisation therapy

#54
20160331705
2016-11-17

Enterically coated cysteamine, cystamine and derivatives thereof

#55
20160331691
2016-11-17

Enterically coated cysteamine, cystamine and derivatives thereof

#56
20160279179
2016-09-29

Probiotic recolonisation therapy

#57
20160279178
2016-09-29

Probiotic recolonisation therapy

#58
20160235673
2016-08-18

Delayed release pharmaceutical formulation containing porous carrier particles for colon targeting

#59
20160183524
2016-06-30

RODENTICIDE

#60
20160151433
2016-06-02

Probiotic recolonisation therapy

#61
20160151432
2016-06-02

Probiotic recolonisation therapy

#62
20160151431
2016-06-02

Probiotic recolonisation therapy

#63
20160151429
2016-06-02

Probiotic recolonisation therapy

#64
20160151310
2016-06-02

Enterically coated cysteamine, cystamine and derivatives thereof

#65
20150335763
2015-11-26

HMGB1-BINDING BEADS AND USES THEREOF

#66
20150306155
2015-10-29

Probiotic recolonisation therapy

#67
20150238546
2015-08-27

Probiotic recolonisation therapy

#68
20150125534
2015-05-07

IMATINIB SOLID DOSAGE FORMS RECONSTITUTED JUST BEFORE USE

#69
20150125526
2015-05-07

Use of Cysteamine and Derivatives Thereof to Treat Mitochondrial Diseases

#70
20150064263
2015-03-05

COMPOSITIONS AND METHODS FOR REDUCTION OF MERCURY TOXICITY

#71
20150017238
2015-01-15

Methods and compositions for treating diabetes

#72
20140227358
2014-08-14

ORGANIC COMPOUNDS

#73
20140220144
2014-08-07

Orally disintegrating tablet compositions of lamotrigine

#74
20140050797
2014-02-20

Drug delivery systems comprising solid solutions of weakly basic drugs

#75
20130108703
2013-05-02

Orally disintegrating tablet compositions of lamotrigine

#76
20120298575
2012-11-29

Anti-fouling materials based on poly(β-peptoid)s

#77
20120288559
2012-11-15

ORGANIC COMPOUNDS

#78
20120237599
2012-09-20

ENTERICALLY COATED CYSTEAMINE, CYSTAMINE AND DERIVATIVES THEREOF

#79
20120015038
2012-01-19

Enterically coated cysteamine, cystamine and derivatives thereof

#80
20110104270
2011-05-05

Process for production of spherical microparticles comprising tamsulosin hydrochloride

#81
20110059122
2011-03-10

Inhibition of the Survival of Oral Cavity Cancer by Cyclohexenone Compounds from Antrodia Camphorata

#82
20100303905
2010-12-02

Orally disintegrating tablet compositions of lamotrigine

#83
20100275502
2010-11-04

Rodenticide

#84
20100268191
2010-10-21

Drug Delivery Catheter using Frangible Microcapsules and Delivery Method

#85
20100040678
2010-02-18

ORGANIC COMPOUNDS

#86
20090092672
2009-04-09

Orally disintegrating tablet compositions of lamotrigine

#87
20090076166
2009-03-19

Enterically coated cystamine, cysteamine and derivatives thereof

#88
20080107748
2008-05-08

Microcapsules for removing and absorbing a chemical from a mixture

#89
20080069878
2008-03-20

Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs

#90
20070259023
2007-11-08

Insulin compensated nutrition

#91
20070197491
2007-08-23

Method for treating primary and secondary forms of glaucoma

#92
16457746
2020-03-17

Transdermal formulation for the treatment of pain and/or inflammation

#93
14463776
2017-07-11

Single solid oral dosage forms for treating infection and duodenal ulcer disease